Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ763850B2 - Improved immunoglobulin variable domains - Google Patents
[go: Go Back, main page]

NZ763850B2 - Improved immunoglobulin variable domains - Google Patents

Improved immunoglobulin variable domains Download PDF

Info

Publication number
NZ763850B2
NZ763850B2 NZ763850A NZ76385015A NZ763850B2 NZ 763850 B2 NZ763850 B2 NZ 763850B2 NZ 763850 A NZ763850 A NZ 763850A NZ 76385015 A NZ76385015 A NZ 76385015A NZ 763850 B2 NZ763850 B2 NZ 763850B2
Authority
NZ
New Zealand
Prior art keywords
heavy
seq
amino acid
chain isvd
chain
Prior art date
Application number
NZ763850A
Other versions
NZ763850A (en
Inventor
Carlo Boutton
Marie Ange Buyse
Original Assignee
Ablynx Nv
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of NZ763850A publication Critical patent/NZ763850A/en
Publication of NZ763850B2 publication Critical patent/NZ763850B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Heavy-chain immunoglobulin single variable domain (ISVD), in which the amino acid residue at position 89 is L and the amino acid residue at position 110 is K or Q, wherein the amino acid residues/positions are indicated with the numbering according to Kabat.

Claims (37)

1. Heavy-chain immunoglobulin single variable domain (ISVD), in which the amino acid residue at position 89 is L and the amino acid residue at position 110 is K or Q, wherein the amino acid residues/positions are indicated with the numbering according to Kabat.
2. Heavy-chain ISVD according to claim 1, that contains an amino acid residue at position 11 that is chosen from L, E, K or Y.
3. Heavy-chain ISVD according to any of claims 1 to 2, that contains an amino acid at position 112 that is S.
4. Heavy-chain ISVD according to any of claims 1 to 3, that contains a Q108L substitution.
5. Heavy-chain ISVD according to any of claims 1 to 4, in which said heavy-chain ISVD contains a C-terminal extension (X)n , in which n is 1 to 10; and each X is an amino acid residue that is independently chosen.
6. Heavy-chain ISVD according to claim 5, in which n is 1, 2, 3, 4 or 5.
7. Heavy-chain ISVD according to claim 5, in which n is 1 or 2.
8. Heavy-chain ISVD according to claim 5, in which n is 1.
9. Heavy-chain ISVD according to any of claims 5 to 8, in which each X is a naturally occurring amino acid.
10. Heavy-chain ISVD according to any of claims 5 to 8, in which each X is independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
11. Heavy-chain ISVD according to any of claims 1 to 10, in which the C-terminal end of the heavy-chain ISVD is one of: VKVSS (SEQ ID NO: 95), VKVSS(X)n (SEQ ID NO:97) and VQVSS (SEQ ID NO: 96), VQVSS(X)n (SEQ ID NO: 98), in which n is 1 to 10; and each X is an amino acid residue that is independently chosen.
12. Heavy-chain ISVD according to claim 11, in which n is 1, 2, 3, 4 or 5.
13. Heavy-chain ISVD according to claim 11, in which n is 1 or 2.
14. Heavy-chain ISVD according to claim 11, in which n is 1.
15. Heavy-chain ISVD according to any of claims 11 to 14, in which each X is a naturally occurring amino acid.
16. Heavy-chain ISVD according to any of claims 11 to 14, in which each X is independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
17. Heavy-chain ISVD, in which: - the amino acid residue at position 11 is one of K, L and V; and - the amino acid residue at position 14 is one of A and P; and - the amino acid residue at position 41 is one of A and P; and - the amino acid residue at position 89 is L; and - the amino acid residue at position 108 is one of Q and L; and - the amino acid residue at position 110 is one of K and Q; and - the amino acid residue at position 112 is S, wherein the amino acid residues/positions are indicated with the numbering according to Kabat.
18. Heavy-chain ISVD according to claim 17, in which the amino acid residue at position 112 is S.
19. Heavy-chain ISVD according to any of claims 17 to 18, in which said heavy-chain ISVD contains a C-terminal extension (X)n, in which n is 1 to 10; and each X is an amino acid residue that is independently chosen.
20. Heavy-chain ISVD according to claim 19, in which n is 1, 2, 3, 4 or 5.
21. Heavy-chain ISVD according to claim 19, in which n is 1 or 2.
22. Heavy-chain ISVD according to claim 19, in which n is 1.
23. Heavy-chain ISVD according to any of claims 19 to 22, in which each X is a naturally occurring amino acid.
24. Heavy-chain ISVD according to any of claims 19 to 22, in which each X is independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
25. Heavy-chain ISVD according to any of claims 1 to 24, which is a VHH domain, humanized VHH domain or camelized VH domain.
26. Heavy-chain ISVD according to any of claims 1 to 25, which is directed against Kv1.3, IL-23, OX40L, IgE, CXCR4, HER3, TNF, c-Met, RANKL, CXCR7 or A-beta.
27. Heavy-chain ISVD according to claim 26, which can specifically bind to TNF, and in which: - CDR1 is the amino acid sequence TADMG (SEQ ID NO:335); - CDR2 is the amino acid sequence RISGIDGTTYYDEPVKG (SEQ ID NO:336); - CDR3 is the amino acid sequence PRYADQWSAYDY (SEQ ID NO:337).
28. Heavy-chain ISVD according to claim 27, that comprises or consists of one of SEQ ID NOs: 338-339 and 346-347.
29. Heavy-chain ISVD according to claim 26, which can specifically bind to TNF, and in which: - CDR1 is the amino acid sequence DYWMY (SEQ ID NO:317); - CDR2 is the amino acid sequence EINTNGLITKYPDSVKG (SEQ ID NO:318); - CDR3 is the amino acid sequence SPSGFN (SEQ ID NO:319).
30. Heavy-chain ISVD according to claim 29, that comprises or consists of one of SEQ ID NOs: 320-321 and 328-329.
31. Heavy-chain ISVD according to any of claims 1 to 25, which can specifically bind to human serum albumin.
32. Heavy-chain ISVD according to claim 31, in which: - CDR1 is the amino acid sequence SFGMS (SEQ ID NO:41); - CDR2 is the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO:42); and - CDR3 is the amino acid sequence GGSLSR (SEQ ID NO:43).
33. Heavy-chain ISVD according to any of claims 31 or 32, in which the amino acid residue at position 89 is L and the amino acid residue at position 110 is K or Q, which can specifically bind to human serum albumin, and which heavy-chain ISVD has at least 80% sequence identity with at least one of Alb-1 (SEQ ID NO: 52 of , SEQ ID NO: 767 in the present specification), Alb-8 (SEQ ID NO: 46) and/or Alb-23 (SEQ ID NO:61).
34. Heavy-chain ISVD according to claim 33, which has at least 85% sequence identity with at least one of Alb-1 (SEQ ID NO: 52 of , SEQ ID NO: 767 in the present specification), Alb-8 (SEQ ID NO: 46) and/or Alb-23 (SEQ ID NO:61).
35. Heavy-chain ISVD according to claim 33, which has at least 90% sequence identity with at least one of Alb-1 (SEQ ID NO: 52 of , SEQ ID NO: 767 in the present specification), Alb-8 (SEQ ID NO: 46) and/or Alb-23 (SEQ ID NO:61).
36. Heavy-chain ISVD according to claim 33, which has at least 95% sequence identity with at least one of Alb-1 (SEQ ID NO: 52 of , SEQ ID NO: 767 in the present specification), Alb-8 (SEQ ID NO: 46) and/or Alb-23 (SEQ ID NO:61).
37. Heavy-chain ISVD according to any of claims 31 to 36, that comprises or consists of one of SEQ ID NOs: 123-136, 496-497, 500, 505-506, and 509.
NZ763850A 2015-05-13 Improved immunoglobulin variable domains NZ763850B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201462014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16
NZ726448A NZ726448B2 (en) 2015-05-13 Improved immunoglobulin variable domains

Publications (2)

Publication Number Publication Date
NZ763850A NZ763850A (en) 2024-08-30
NZ763850B2 true NZ763850B2 (en) 2024-12-03

Family

ID=

Similar Documents

Publication Publication Date Title
IL299282A (en) Improved immunoglobulin variable domains
IL259927B1 (en) Humanized anti-cd73 antibodies
MX2019007719A (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier.
RU2018133708A (en) BTLA SPECIFIC ANTIBODIES AND THEIR USE
RU2014143785A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF LIVER CANCER
MX2017004970A (en) Antibodies that bind to ccr6 and their uses.
MX2019003890A (en) Antibodies with reduced binding to process impurities.
HRP20210604T1 (en) Humanized anti-hmgb1 antibody or antigen-binding fragment thereof
NZ763850B2 (en) Improved immunoglobulin variable domains
NZ763850A (en) Improved immunoglobulin variable domains
WO2018088403A8 (en) Fragment antibody and method for crystallizing protein using fragment antibody
NZ763845B2 (en) Improved immunoglobulin variable domains
NZ726448B2 (en) Improved immunoglobulin variable domains
NZ763852B2 (en) Improved immunoglobulin variable domains
NZ763848B2 (en) Improved immunoglobulin variable domains
NZ743471B2 (en) Improved immunoglobulin variable domains
NZ780173B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ780173A (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RU2023116046A (en) METHODS FOR PREDICTING, DETECTING AND REDUCING NON-SPECIFIC PROTEIN INTERFERENCE IN ANALYSIS METHODS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS
RU2024118294A (en) METHODS FOR PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC PROTEIN INTERFERENCE IN ANALYSIS METHODS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS
NZ734798A (en) Polypeptides
TH1901007069A (en) GARP-TGF-beta antibody
NZ766849B2 (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ766849A (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ730014B2 (en) Compound targeting il-23a and tnf-alpha and uses thereof